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Abstract
In the face of finite resources, allocations of research and health-care funding are dependent upon high-quality evidence.
Historically, tinnitus has been the poor cousin of hearing science, with low-quality clinical research providing unreliable
estimates of effect and with devices marketed for tinnitus without strong evidence for those product claims. However, the
tinnitus field is changing. Key opinion leaders have recently made calls to the field to improve the design, implementation, and
reporting of clinical trials, and there is growing intersectoral collaboration. The Tonndorf Lecture presented at the 1st World
Tinnitus Congress and the 12th International Tinnitus Seminar in Warsaw, Poland, provided an opportunity to reflect on the
present and future progress of tinnitus research and treatment and what is needed for the field to achieve success.
The content of that lecture is summarized in this article. The main debate concerns the selection and reporting of outcomes
in clinical trials of tinnitus. Comprehensive reviews of the literature confirm the diversity of the personal impact of tinnitus
and illustrate a lack of consensus in what aspects of tinnitus should be assessed and reported in a clinical trial. An innovative
project is described which engages the global tinnitus community (patients and professionals alike) in working together.
This project seeks to improve future tinnitus research by creating an evidence-based consensus about minimum reporting
standards for outcomes in clinical trials of a tinnitus intervention. The output will be a core set of important and critical
outcomes to be measured and reported in all clinical trials.
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Introduction
Every patient with tinnitus presents with a complex array
of symptoms and functional impacts which reﬂects their
own personal experience. The need for eﬀective manage-
ment options that cope with this heterogeneity in the
clinical population has been widely recognized for
many decades. For example, in his 1999 Tonndorf
Lecture on the use of science to ﬁnd successful tinnitus
treatments, Richard Tyler (1999) looked ahead to a
future in which a persuasive tinnitus treatment would
be one that shows a large treatment eﬀect, could be
generalized across patients and clinicians, and would be
speciﬁc and credible. Wide variability within individual
patients tested over repeated assessments and large dif-
ferences between patients allocated to a treatment group
contribute to small overall treatment eﬀects and lack of
replicability of treatment-related ﬁndings across studies.
Moreover, progress has generally been hampered by low
quality in standards of design, conduct, and reporting of
intervention trials, introducing an unacceptable risk of
bias.
This situation thwarts attempts to make useful
recommendations and practical guidelines for family
medicine and primary health-care practitioners.
Although there are a number of good practice guidelines
for tinnitus (recently reviewed in Fuller et al., 2017),
many therapeutic options are without evidence for
1Otology and Hearing Group, Division of Clinical Neuroscience, School of
Medicine, University of Nottingham, UK
2Institute for Health Research (NIHR) Nottingham Biomedical Research
Centre, UK
3Nottingham University Hospitals NHS Trust, Queen’s Medical Centre, UK
Corresponding author:
Deborah A. Hall, Institute for Health Research (NIHR) Nottingham
Biomedical Research Centre, Ropewalk House, 113 The Ropewalk,
Nottingham NG1 5DU, UK.
Email: deborah.hall@nottingham.ac.uk
Trends in Hearing
Volume 21: 1–12
! The Author(s) 2017
DOI: 10.1177/2331216517736689
journals.sagepub.com/home/tia
Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/
4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and
Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
their eﬀectiveness. Furthermore, several recent
systematic reviews evaluating the therapeutic beneﬁts
of speciﬁc interventions for tinnitus and published by
Cochrane have shown that reporting is still ﬂawed by
poor methodology and poor reporting (e.g., Hilton,
Zimmermann, & Hunt, 2013; Hoare, Edmondson-
Jones, Sereda, Akeroyd, & Hall, 2014; Person, Puga,
da Silva, & Torloni, 2016). Systematic reviews provide
the highest level of evidence for treatment eﬀectiveness,
but rely on randomized controlled trials (RCTs) with a
justiﬁed sample size and beneﬁt from consistent use and
reporting of common outcomes across studies. Indeed, a
common conclusion for Cochrane reviews of tinnitus
interventions is that ‘‘more high quality research is
needed’’ because ﬁndings are inconclusive.
The Consolidated Standards of Reporting Trials
(CONSORT) group provides perhaps the most
well-known guidelines for solving problems arising
from inadequate reporting of RCTs (CONSORT,
2017), and it has been endorsed by prominent general
medical journals, many specialty medical journals, and
leading editorial organizations. The CONSORT
statement is an evidence-based minimum set of recom-
mendations which provide a standard way for authors to
prepare reports of trial ﬁndings (see Moher et al., 2010
for further details). The statement comprises (a) a 25-
item checklist which can be followed to help report
how the trial was designed, analyzed, and interpreted
and (b) a ﬂow diagram which helps to clearly illustrate
how all participants progressed through the trial
(including those who were screened but not randomized
and those who withdrew and did not complete). The
CONSORT statement seeks to facilitate authors’ com-
plete and transparent reporting and aid their critical
appraisal and interpretation. However, it does not
appear to have had widespread uptake within the tin-
nitus community. To illustrate this point, a search,
conducted using the U.S. National Library of Medicine
National Institutes of Health PubMed database (on
September 17, 2017), revealed only two publications
(i.e., Hoare, Pierzycki, Thomas, McAlpine, & Hall,
2013; Stein et al., 2016) which contained the term
‘‘CONSORT’’ out of 11,372 possible articles on ‘‘tin-
nitus,’’ when these two search terms were cospeciﬁed to
be present in any ﬁeld.
Comparable tinnitus-centered statements have been
around since the 1990s, and many of these recommenda-
tions are applicable to a range of trial designs, not just
RCTs; they can even apply to the reporting of retrospect-
ive studies (Londero & Hall, 2017). In our recent
Opinion article, we pooled together relevant concluding
remarks or recommendations that had been taken from
numerous review articles published by health-care and
research leaders across the tinnitus community.
Looking speciﬁcally at those comments about clinical
trial outcomes in tinnitus, we noted that many of the
authors repeat the same sort of advice. This indicates
to us that these recommendations have probably not
yet been very successful in transforming standards in
the tinnitus ﬁeld. As Andre´ Gide (French author,
1869–1951) said: ‘‘Everything that needs to be said has
already been said. But since no one was listening, every-
thing must be said again.’’
A Quest to Create a Legacy
An evidence-based hearing health-care system uses cur-
rent best scientiﬁc evidence about what works best in
making decisions about the care of the individual
patient. To create that evidence, investigators test out
interventions in clinical trials to make sure they work
and are safe for patients. This is achieved by measuring
‘‘outcomes.’’ ‘‘Outcomes’’ refer collectively to those
aspects of the condition that are chosen to assess how
well the treatment has worked and the corresponding
instruments for measuring them. Hence, outcomes have
two facets. The ﬁrst facet is the outcome domain, and this
is deﬁned as a complaint of tinnitus that is a distinct
theoretical construct. Examples include how loud or
how emotionally distressing a patient may ﬁnd his or
her tinnitus. The second facet is the outcome instrument,
and this is deﬁned as a tool used to assess and quantify
the outcome domain. Outcomes can include aspects of
the tinnitus sensation itself as well as the reactions to the
tinnitus. Ideally, the primary outcome domains assessed
in a clinical trial should be of importance to patients as
well as health professionals, and outcome instruments
should be reliable, validated, and responsive to treat-
ment-related change. In any piece of clinical research,
selecting and reporting outcomes are perhaps the most
critical aspects. William Noble (2001, p. 20) perfectly
summarized the importance of this issue when he
wrote: ‘‘Critical to any form of treatment for tinnitus is
the reliance placed on measures to assess the eﬀectiveness
of the intervention.’’ At worst, a study may fail because
the outcome is inappropriate, not because the treatment
is ineﬀective.
Over recent years, our work has focused on the issues
of outcome domains and outcome instruments, speciﬁc-
ally seeking to establish an evidence-based consensus
about minimum reporting standards for outcomes in
clinical trials that are evaluating any tinnitus interven-
tion. To aid in this eﬀort, a call was made to invite tin-
nitus experts representing diﬀerent disciplines, diﬀerent
centers, and diﬀerent countries to work together toward
more consistent, evidence-based outcomes (Hall et al.,
2015a). It is hoped that by actively seeking to engage
directly with the international, multidisciplinary commu-
nity in discussion, in research projects, and in consensus
building, we can collectively create a set of research
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recommendations about minimum reporting standards
that will be suﬃciently inﬂuential for others to adopt
of those ideas and recommendations into practice. This
approach should enhance the likelihood of adoption of
any recommendations, more so than simply relying on
conventional dissemination channels, such as conference
presentations and journal publications.
Harnessing the international community to collect-
ively work toward solving some of these challenges is
particularly important because unlike almost any other
ﬁeld of hearing health care, tinnitus is a topic of special
interest to general practitioners; ear, nose, and throat
physicians; audiologists; psychologists; neurologists;
radiologists; and psychiatrists, as well as academic
researchers and commercial representatives from the
medical device and pharmaceutical sectors (Hall et al.,
2011). A worthwhile legacy for tinnitus research would
be to agree on a common conceptual framework and
language for outcomes that is accessible and relevant
to all relevant stakeholder groups.
Trial Design Matters
In their Commentary on the status of systematic reviews,
Clarke and Williamson (2016) noted that one of the
greatest barriers to comparing, contrasting, and combin-
ing the ﬁndings of the existing research studies is the
inconsistent use of outcome measures from one study
to another. The ﬁeld of tinnitus is no exception. For
example, we found 133 diﬀerent outcome instruments
in use across clinical trials in tinnitus (Hall et al., 2016)
and the existence of at least 29 diﬀerent questionnaires
that can be completed by patients to quantify an indi-
vidual’s tinnitus symptoms (Haider, Fackrell, Kennedy,
& Hall, 2016).
Which one(s) should be recommended for measuring
treatment eﬀects? Current advice is somewhat contra-
dictory. For example, a small but inﬂuential group of
tinnitus experts produced a statement that encompassed
recommendations about the choice of treatment out-
come measurement instruments (Langguth et al., 2007).
The statement was that one standardized questionnaire
should be used to measure treatment-related outcomes in
all therapeutic trials, which is validated in many lan-
guages and in many cultural and socioeconomic
groups. Recommendations at the time were for one of
the following: Tinnitus Handicap Inventory, Tinnitus
Handicap Questionnaire, Tinnitus Reaction
Questionnaire, or the Tinnitus Questionnaire. However,
the recommendations were not based on any review of
the statistical performance of these instruments. Much
less cited, perhaps because it is less well known, is a sys-
tematic review of the psychometric properties of these
four questionnaires (Kamalski, Hoekstra, van Zanten,
Grolman, & Rovers, 2010). Based on their ﬁndings, the
authors called into question the validity, reliability, and
responsiveness of these instruments for assessing treat-
ment-related change (see also Fackrell, Hall, Barry, &
Hoare, 2014). They recommended that more work be
done before final conclusions are drawn regarding the
utility of these speciﬁc questionnaires in future clinical
studies. The American Academy of Otolaryngology
Head and Neck Surgery (AAO-HNS) has echoed this
research need. Following the publication of its clinical
guideline of evidence-based recommendations for mana-
ging tinnitus (Tunkel et al., 2014), the organization also
published a long list of research needs. Recommendations
reiterated the need for further research to determine which
instrument is most useful for assessing relevant treatment
eﬀects and also promoted the inclusion of a generic
quality-of-life measure into clinical trials of tinnitus inter-
ventions to assess the net impact of any treatment-related
beneﬁts and harms (AAO-HNS, 2017). As a general rule,
questionnaire instruments that successfully measure thera-
peutic beneﬁt in diﬀerent situations tend to be those with
good statistical properties that enable the clinician or
investigator to interpret speciﬁc complaints rather than
those measuring a multidimensional health construct
(Prinsen et al., 2016).
In Europe, a TINnitus NETwork (TINNET) consor-
tium has been formed to address this research need by
establishing standards for clinical trials in tinnitus. The
consortium was established through an EU COST
Action funding (BM1306, 2014–2018) and supports the
COMiT (Core Outcome Measures in Tinnitus) initia-
tive—a network of partners interested in outcomes. As
already indicated, intentions to compare, contrast, and
combine the ﬁndings of existing research studies are
often thwarted by inconsistencies in the outcomes that
were measured and reported in the individual studies.
This, in turn, makes it diﬃcult for the tinnitus commu-
nity to make informed decisions and choices about
eﬀective health and social care. One solution would be
for tinnitus trials to measure and report a standardized
set of outcomes, which would then also be used in sys-
tematic reviews (Clarke & Williamson, 2016). We pub-
lished a roadmap that set out the research process by
which we hope to achieve an evidence-based consensus
on a standardized collection of tinnitus-related outcomes
(Hall et al., 2015a). An updated summary of that road-
map is given in Figure 1. The roadmap was accompanied
with a call inviting tinnitus experts to engage with the
COMiT initiative (Hall et al., 2015a); the group currently
comprises 46 tinnitus experts from across 17 countries
(TINNET, 2017).
Standardizing Outcome Reporting
The roadmap for establishing standards for outcome
measurements in clinical trials for tinnitus starts with
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outcome domains (Figure 1). The purpose of Step 1 is to
identify and agree on a core set of outcome domains
where all those outcome domains will be measured and
reported in all clinical trials evaluating an intervention
for tinnitus. Step 1 began with two reviews of the litera-
ture: one to understand what tinnitus-related complaints
are relevant to professionals as reported in clinical trials
(Hall et al., 2016; Hall, Szczepek, Kennedy, & Haider,
2015b) and one to understand what tinnitus-related com-
plaints are relevant to patients (Haider et al., 2016).
Professional Perspectives on Tinnitus-Related
Complaints
In the review of research relevant to professionals,
clinical trials of tinnitus were identiﬁed by searching
four of the major electronic databases of scientiﬁc pub-
lications, three international clinical trial registries, and
the Cochrane Database of Systematic Reviews (Hall
et al., 2016). From 2,077 articles identiﬁed, 228 met
our eligibility criteria: (a) published from July 2006 to
March 2015; (b) enrolling adults aged 18 years or older;
(c) participants reported tinnitus as a primary complaint;
(d) RCT design, before and after the study, non-RCT,
case–control study, or cohort study; (e) sample size of at
least 20; and (f) published in English.
According to the reporting of the study design, 61
diﬀerent outcome domains were identiﬁed spanning
seven categories (tinnitus percept, impact of tinnitus,
co-occurring complaints, quality of life, body structures
and function, treatment-related outcomes, and unclear
or not deﬁned). This heterogeneity across studies is
symptomatic of the lack of consensus among tinnitus
experts. Most common were tinnitus loudness (10%,
112 of 1,084) and the eﬀects of tinnitus on feelings of
distress (5%, 51 of 1,084). While the majority of outcome
domains were related to therapeutic beneﬁt, harms were
also assessed and reported (7%, 79 of 1,084). Typically,
reporting was described as ‘‘safety’’ or ‘‘side eﬀects’’ (4%
and 1%, respectively). Of note, in 50% of cases (539 of
1,084), we observed that investigators did not clearly
report the outcome domain of interest. Many times it
was not mentioned at all, while other times it was
merely described as ‘‘tinnitus handicap’’ or ‘‘tinnitus
severity.’’ Tinnitus handicap did not meet the COMiT
initiative’s requirement for an outcome domain because
it refers generally to any disadvantage that limits or pre-
vents the fulﬁlment of a person’s role that is normal. It is
not a distinct theoretical construct. Equally, tinnitus
severity did not meet our requirement because it refers
to the magnitude of the burden of tinnitus on the patient.
It does not deﬁne the complaint itself.
Patient Perspectives on Relevant Tinnitus-Related
Complaints
The main objective of the patient-centric review was to
identify what adults with tinnitus and their signiﬁcant
others report as problems in their everyday lives caused
by tinnitus (Haider et al., 2016; Hall et al., 2017). Studies
Figure 1. An updated summary of the roadmap to establish an international standard for outcome assessment and reporting in early
phase clinical trials of tinnitus, adapted from Hall et al. (2015a). In this scheme, an outcome domain is a complaint of tinnitus that is a
distinct theoretical construct, and an outcome instrument is a tool used to assess and quantify that outcome domain. Instruments are not
limited to questionnaires but can include other tools such as clinician-administered tests.
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were identiﬁed in which participants were enrolled
because tinnitus was their primary complaint. To do
this, electronic searches were conducted in PubMed,
Embase, CINAHL, as well as grey literature sources to
identify publications from January 1980 to June 2015. A
manual search of seven relevant journals then updated
the search to February 2017. Of the 3,638 titles identiﬁed
overall, 81 records (reporting 83 studies) met our inclu-
sion criteria and were taken through to data collection
representing 15,902 study participants with tinnitus.
Coders collated all reported generic and tinnitus-speciﬁc
complaints, which were then synthesized into a list of
items each describing theoretically distinct constructs.
Overall, there were 42 discrete unidimensional patient-
reported complaints. These spanned eight categories
(negative attributes of the tinnitus percept, physical
health problems, functional diﬃculties due to the tin-
nitus, emotional complaints associated with tinnitus-
related distress, negative thoughts about tinnitus, general
mood states such as anxiety and depression, and aspects
of quality of life). Most common were the eﬀects of tin-
nitus on feelings of distress and sleep diﬃculties, but
every complaint is a potential outcome domain that
could be measured in a clinical trial to assess treat-
ment-related change.
These unpublished ﬁndings emphasize the vast array
of personal experiences associated with tinnitus. All these
complaints are candidates to be considered as outcome
domains used to assess whether a treatment has worked.
Examples of these are reported and described in Table 1.
Considerable work has gone into selecting only those
outcome domains which refer to a conceptually distinct
element of tinnitus, excluding broad overarching con-
structs (such as ‘‘Quality of Life’’ or ‘‘Cognitive diﬃcul-
ties’’; Fackrell et al., 2017). In addition, outcome domain
names and plain language descriptions have been copro-
duced with 16 people who have tinnitus and 5 clinical
experts (Fackrell et al., 2017). The list given in Table 1 is
extensive. Clearly, it is not feasible to assess so many
outcome domains in every clinical trial evaluating an
intervention for tinnitus. The list therefore needs to be
reduced to a minimum reporting set, which represents a
small number of outcome domains that the tinnitus com-
munity agree are critically important for assessing thera-
peutic outcome and so should always be assessed and
reported.
Minimum Set of Outcome Domains for Clinical Trials
of Sound-, Psychology-, and Pharmacology-Based
Tinnitus Interventions
To achieve this minimum set of outcome domains, the
ﬁnal part of Step 1 in the roadmap is to reduce the ‘‘long
list’’ described earlier through a consensus approach
involving all key stakeholders (professionals and patients
alike). After discussion with tinnitus health-care
practitioners and commercial representatives, the
COMiT initiative decided that speciﬁc discussions were
needed around the major therapeutic approaches for tin-
nitus (namely, sound-, psychology-, and pharmacology-
based interventions) because they do not necessarily
target the same tinnitus-related complaints (Fackrell
et al., 2017). Our study design therefore includes three
separate surveys, each based on an online Delphi survey
method and each recruiting experts in that particular
therapeutic strategy (Figure 2). This study has been
given a favorable ethics opinion by the West Midlands
Solihull Research Ethics Committee (ref: 17/WM/0095)
and is almost completed. The outcome will be three core
outcome domain sets; one for each intervention cat-
egory. The Delphi survey method is suited to
explore areas where controversy, debate, or a lack of
clarity exist (Iqbal & Pipon-Young, 2009). It has been
used to determine the range of opinions on speciﬁc mat-
ters and to achieve consensus on disputed topics.
Although there is no gold standard for how the Delphi
method is applied, its distinct characteristics are the
following:
1. It recruits a group of participants specially selected
for their particular expertise on a topic;
2. It is often conducted across a series of two or more
sequential questionnaires known as ‘‘rounds,’’ with
Round 1 enabling participants to nominate salient
issues (in this case, candidate outcome domains that
were missing from the ‘‘long list’’);
3. It has an evaluation phase where participants are
provided with a summary of the stakeholder
responses and asked to reevaluate their original
responses; and
4. It is interested in the formation of consensus, often
deﬁned as the number of participants agreeing with
each other on questionnaire items (Iqbal & Pipon-
Young, 2009).
By making the surveys accessible online and through
calls to participate via a range of dissemination channels
(publications, conferences, patient organizations, and
social media), 308 professionals and 366 patients from
across the world have participated in Round 1 of the
Delphi surveys (including 91 from the United States
and Canada and 582 from Europe). Stakeholder
groups are people with lived experience of tinnitus,
health-care practitioners, clinical researchers,
commercial representatives and funders, as well as jour-
nal editors. In Round 1, we asked participants to think
about each one of the distinct outcome domains listed in
Table 1. Participants scored each outcome domain using
the GRADE scale of 1 to 9, where 1 represents least
important and 9 represents most important (Guyatt
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et al., 2011). Selecting response options 1 to 3 indicates
that the domain is not important, while 7 to 9 indicates
that the domain is critically important in deciding
whether a tinnitus treatment is eﬀective. Scores 4, 5,
and 6 indicate the outcome domain is important but not
critical. Participants could also tell us if we had missed
anything, and these would be added as new candidate
outcome domains in Round 2. In Rounds 2 and 3, all
participants received the same list of outcomes with feed-
back tailored according to their stakeholder allocation.
The purpose of Round 2 is to enable participants to
reﬂect on their scores in light of the viewpoint of their
stakeholder peers and to score the outcomes again
(Figure 2). The purpose of Round 3 is to enable partici-
pants to reﬂect on their scores in light of the viewpoint of
their stakeholder peers and all other stakeholder groups
and to score the outcomes again (Figure 2). At the end of
Round 3, if at least 70% of experts of the participants in
each stakeholder group score 7 to 9 agree and fewer than
15% score 1 to 3, then we will recommend that outcome
domain for the intervention-speciﬁc Core Outcome Set
(cf. Williamson et al., 2012).
Consensus meetings, planned for September and
October 2017, will agree on outcome domains to be
included in the Core Outcome Set. There will be one
meeting for each intervention category and a representa-
tive subset of participants will discuss and then vote on
each outcome domain as ‘‘in’’ or ‘‘out.’’ Once we have
identiﬁed a core outcome domain set, the next step in our
roadmap is about selecting ‘‘how’’ and ‘‘when’’ to meas-
ure them. This corresponds to Step 2 in the roadmap
(Figure 1). By ‘‘how’’ we mean what instrument. By
‘‘when’’ we mean is it a short-term change that should
be seen immediately after the treatment, or is it a long-
term change that will be sustained months and years
after treatment. Again, these are decisions to be taken
with consensus across the tinnitus community.
Collectively, the ‘‘what,’’ ‘‘how,’’ and ‘‘when’’ is called
a Core Outcome Set.
Recommendations
The work conducted so far through the COMiT initia-
tive has already enabled us to start making some evi-
dence-based recommendations about reporting
standards. In particular, 17 members met on March 16,
2016 during the ﬁrst EU COST Action TINNET confer-
ence held in Nottingham to discuss the implications of
the evidence base gathered as part of a recent systematic
review of clinical trials of tinnitus interventions for
adults with tinnitus (Hall et al., 2016; Hall et al.,
2015b). From this evidence base, we highlighted a
number of suggestions to the tinnitus community con-
cerning the speciﬁcation and reporting of outcomes in
clinical trials (TINNET, 2016). The aim of our simpleT
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guidelines is to harmonize the reporting of clinical trial
outcomes for tinnitus. These recommendations are
intended not only for investigators’ designing and report-
ing trials but also for journal editors and journal
reviewers who play an important role in the publication
process.
Prespecify the Primary Determinant(s) of Clinical
Effectiveness
The simplest and most common trial design is where one
primary outcome domain determines whether or not
the intervention is judged to be eﬀective. For example,
the main goal of an intervention may be to improve the
quality of sleep. But sometimes an intervention can be
intended to have a positive inﬂuence on more than one
distinct tinnitus-related complaint (such as reducing tin-
nitus loudness, and tinnitus intrusiveness, and sense of
control). In that scenario, investigators would therefore
have a good motivation to measure all three outcomes in
a trial. The default expectation would then be that all
three outcomes should demonstrate a signiﬁcant
reduction in order to drive any conclusions about the
therapeutic beneﬁt. If there is no clear a priori proposal
to treat the three outcomes diﬀerently, then if only one
showed a signiﬁcant reduction, there is a risk that this
will be emphasized in the reporting, while the other two
are downplayed. This is what CONSORT (2017) calls
‘‘risk of bias in outcome reporting.’’ And if such a trial
was included in a systematic review, then this would
present a source of potential methodological concern.
To minimize outcome reporting bias, investigators
should specify a priori which of the potential tinnitus-
related complaints will determine the conclusion about
treatment eﬀectiveness, and how the ﬁndings will be
interpreted. Any number of additional outcomes can
be deﬁned either as secondary outcomes or exploratory
outcomes, but these would not be expected to drive any
conclusions about therapeutic beneﬁt.
Describe ‘‘What,’’ ‘‘How,’’ and ‘‘When’’
For reporting the primary outcome(s) at least, the
COMiT initiative has endorsed a simple formula that
considers what is measured, how it is measured, and
when it is measured. Table 2 provides several worked
examples.
What: For trials of clinical eﬃcacy and eﬀectiveness,
investigators should clearly specify what they expect
their intervention to change. Examples include ‘‘how
loud the tinnitus is perceived’’ or ‘‘how distressed the
person feels by their tinnitus.’’ These speciﬁc dimensions
Figure 2. A schematic diagram of the online Delphi process, including Rounds 1 to 3 and the face-to-face consensus meetings. The
colored histograms represent the planned graphical format of the results from the previous round. Single (yellow) histogram represents
results for the peer stakeholder group. Purple, green, and red histograms represent results for each relevant stakeholder group (peer and
otherwise).
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or domains of tinnitus-related complaint deﬁne the clin-
ical trial outcome.
How: For each outcome, investigators should clearly
specify how that outcome domain will be measured.
In other words, which speciﬁc instrument will be used
to measure change in that tinnitus-related complaint,
and preferably that instrument should have been evalu-
ated for responsiveness to treatment-related change in
the appropriate patient population because just because
it is shown to be sensitive in one population does
not necessarily mean it is sensitive in another (Fackrell,
Hall, Barry, & Hoare, 2016). It is also preferable to pro-
vide some explanation about why that particular instru-
ment was selected.
When: For each outcome of interest, investigators
should clearly specify when the outcome will be
measured. In our review of tinnitus trials, we found
this information particularly diﬃcult to extract from
published reports (Hall et al., 2016), and to avoid con-
fusion, we suggest that it is preferable to describe the end
point relative to the start (not the end) of the interven-
tion period. This avoids any misinterpretation about the
timescales between the pre- and postintervention
assessments.
Patient Harms Are Important Too
Cuervo and Clarke (2003) said that ‘‘Reporting harms
may cause more trouble and discredit than the fame and
glory associated with successful reporting of beneﬁts (1).
Reporting harms may cause more trouble and discredit
than the fame and glory associated with successful
reporting of beneﬁts’’ (p. 66). Perhaps then it is no
surprise that in our review of tinnitus trials we found
very little published information about the negative
eﬀects of the intervention of interest (Hall et al., 2016).
Yet, the purpose of a trial is to collect and appropriately
report good and bad events and outcomes so that they
may be compared across treatment groups (Ioannidis
et al., 2004). In addition to providing reliable evidence
on the beneﬁcial eﬀects of an intervention, it is just as
important to provide reliable information about its
harms. Harms can be thought of as the direct opposite
of beneﬁts and examples include withdrawals and
adverse events. We highlight an extension of the
CONSORT statement that gives guidance on reporting
harms (Ioannidis et al., 2004). Harms is the preferred
term over ‘‘safety’’ or ‘‘side eﬀects.’’ This is because
safety refers to substantive evidence for the absence of
harm, not the absence of evidence of harm, while side
eﬀects imply that the harms are caused by the interven-
tion. Yet this is not always known.
Concluding Remarks
The recommendations endorsed by the COMiT initiative
are consistent with international reporting guidelines
aiming at positively inﬂuencing the quality of published
research reports for RCTs. The CONSORT statement is
extremely helpful (CONSORT, 2017; Moher et al.,
2010). The CONSORT statement can also be used to
guide reporting other trial designs, including parallel
non-randomized trials and cross-over designs. Readers
might ﬁnd it useful to know that the EQUATOR net-
work (Enhancing the QUAlity and Transparency Of
health Research) maintains an up-to-date library of
this and other reporting guidelines and toolkits for
authors (www.equator-network.org).
The COMiT initiative is open to views from all
stakeholders interested in the development of Core
Outcome Sets for tinnitus. There is a strong passion
and shared optimism for working together and engaging
with tinnitus experts outside the European Union in
order to ensure that our recommendations truly reﬂect
an international consensus. We particularly encourage
health-care practitioners and researchers from North
America, Australasia, Asia, and Africa to act as a
national advocate for the project and to help us spread
the adoption and implementation of our recommenda-
tions as a model of good practice.
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